Trial Profile
A multi-center study to examine the pharmacokinetics, whole body and organ dosimetry, and biodistribution of fission-derived iodine I 131 tositumomab for patients with previously untreated or relapsed follicular or transformed follicular non-hodgkin's lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Iodine-131 tositumomab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 08 Mar 2008 New trial record.